ATG-107 / Antengene - LARVOL DELTA

ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML (SITC 2024) - "BMK is an analog of CLN-049, produced using sequences from the patent WO2020053300A1. WT, wildtype; ITD, Internal tandem duplication. Antibody induced T cell activation (middle) and T cell dependent cellular cytotoxicity (TDCC, bottom) in presence of EOL-1, THP-1, MOLM-13 and MV4-11 were also shown in D, E, F and G, respectively"

Preclinical • Acute Myelogenous Leukemia • Oncology • CD69 • FLT3 • IL2RA

ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML (SITC 2024) - "BMK is an analog of CLN-049, produced using sequences from the patent WO2020053300A1. WT, wildtype; ITD, Internal tandem duplication. Antibody induced T cell activation (middle) and T cell dependent cellular cytotoxicity (TDCC, bottom) in presence of EOL-1, THP-1, MOLM-13 and MV4-11 were also shown in D, E, F and G, respectively"

Preclinical • Acute Myelogenous Leukemia • Oncology • CD69 • FLT3 • IL2RA

Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML (PRNewswire) - "Antengene Corporation Limited...announced that it will present results from...programs at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC 2024)....Abstract Number: 1068:....ATG-107 binds bivalently to FLT3, concealing the CD3 binding site until FLT3 is engaged. Preclinical studies showed strong T-cell activation and cytotoxicity against AML cells, regardless of FLT3 mutation status, and potent in vivo anti-AML efficacy in PBMC humanized mouse models. ATG-107 presents a promising therapeutic strategy for a broad AML patient population, offering FLT3-dependent T-cell activation and potent preclinical efficacy."

Preclinical • Acute Myelogenous Leukemia

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting (PRNewswire) - "Antengene Corporation Limited...announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024."

Preclinical • Acute Myelogenous Leukemia